Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial

Lancet Oncology

Volumn 7, Issue 7, 2006, Pages 547-555

  Ronco, Guglielmo ^a   Giorgi Rossi, Paolo ^b   Carozzi, Francesca ^c   Dalla Palma, Paolo ^d   Del Mistro, Annarosa ^e   De Marco, Laura ^a,f   De Lillo, Margherita ^g   Naldoni, Carlo ^h   Pierotti, Paola ⁱ   Rizzolo, Raffaella ^a   Segnan, Nereo ^a   Schincaglia, Patrizia ^j   Zorzi, Manuel ^e   Confortini, Massimo ^c   Cuzick, Jack ^k  

^a Centre for Cancer Prevention   (Italy)

^b Agency for Public Health   (Italy)

^c CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^d SANTA CHIARA HOSPITAL   (Italy)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g AUSL Imola   (Italy)

^h Regione Emilia Romagna   (Italy)

ⁱ MAGGIORE HOSPITAL   (Italy)

^j AUSL Ravenna   (Italy)

^k QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; AGE; ARTICLE; CANCER GRADING; CANCER SCREENING; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; EMERGENCY HEALTH SERVICE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT REFERRAL; PATIENT SELECTION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS IDENTIFICATION; WART VIRUS;

ADULT; AGE FACTORS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 33745278233     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70731-8     Document Type: Article

References (24)

1. Cuzick J., Szarewski A., Terry G., et al. Human papillomavirus testing in primary cervical screening. Lancet 345 (1995) 1533-1536
2. Clavel C., Masure M., Bory J., et al. Hybrid capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 80 (1999) 1306-1311
3. Cuzick J., Beverley E., Ho L., et al. HPV testing in primary screening of older women. Br J Cancer 81 (1999) 554-558
4. Clavel C., Masure M., Bory J., et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 84 (2001) 1616-1623
5. Ratnam S., Franco E., and Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 9 (2000) 945-951
6. Kuhn L., Denny L., Pollack A., et al. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 92 17 (2000) 818-825
7. Schiffman M., Herrero R., Hildesheim A., et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 283 (2000) 87-93
8. Schneider A., Hoyer H., Lotz B., et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 89 (2000) 529-534
9. Denny L., Kuhn L., Pollack A., et al. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 89 (2000) 826-833
10. Kulasingam S., Hughes J., Kiviat N., et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288 (2002) 1749-1757
11. Cuzick J., Szarewski A., Cubie H., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362 (2003) 1871-1876
12. Petry K., Menton S., Menton M., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 88 (2003) 1570-1577
13. Salmeron J., Lazcano-Ponce E., Lorincz A., et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 14 (2003) 505-512
14. Davey E., Barrat A., Irwig L., et al. Effect of study design and quality on unsatisfactory rates, cytological classification, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 367 (2006) 122-132
15. Davies P., Arbyn M., Dillner J., et al. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer 118 (2006) 791-796
16. Ronco G., Segnan N., Giorgi-Rossi P., et al., the NTCC Working Group. Human papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst 98 (2006) 765-774
17. Kotaniemi-Talonen L., Nieminen P., Anttila A., and Hakama M. Routine screening with primary HPV testing and cytology triage protocol in a randomised setting. Int J Cancer 93 (2005) 862-867
18. Richardson H., Kelsall G., Tellier P., et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12 (2003) 485-490
19. Sellors J., Karwalajtys T., Kaczorowski J., et al., Survey of HPV in Ontario women group. Incidence, clearance and predictors of human papilloma virus infection in women. CMAJ 168 (2003) 421-425
20. Elfgren K., Rylander E., Radberg T., et al., for the Sweedscreen Study Group. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyrybonucleic acid persistence. Am J Osbtet Gynecol 193 (2005) 650-657
21. Franco E., Villa L., Sobrinho J., et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high risk area for cervical cancer. J Infect Dis 180 (1999) 1415-1423
22. van Duin M., Snijders P., Schrijnemakers H., et al. Human papillomavirus 16 load and abnormal cervical scrapes: an indicator of CINII/III and viral clearance. Int J Cancer 98 (2002) 950-959
23. Molano M., van den Brule A., Plummer M., et al., HPV study group. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology; a population based 5-year follow-up study. Am J Epidemiol 158 (2003) 46-94
24. Nobbenhuis M., Helmerhorst T., van den Brule A., et al. Cytological regression and clearance of high-risk human papillomavirus in women with abnormal cervical smears. Lancet 358 (2001) 1782-1783